Remdesivir as a potent antiviral against prototype and current epidemic Oropouche virus strains (BeAn19991 and PE-IAM4637)
Virus Research · 2026-01 · 363 · 199680
DOI: 10.1016/j.virusres.2025.199680 ↗Kurz gefasst
Fachartikel in der Zeitschrift Virus Research, 2026-01. Verfasst von Rokusuke Yoshikawa und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Emerging Infectious Diseases, Institute of Tropical Medicine (NEKKEN), Nagasaki University, Nagasaki, Japan; Department of Emerging Inf…. Hauptthemen laut MEDLINE: Antiviral Agents, Orthobunyavirus, Alanine, Adenosine Monophosphate. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Society for the Promotion of Science, Japan Agency for Medical Research and Development, Japan Science and Technology Agency.
Abstract (Originalsprache)
The Oropouche virus (OROV), an orthobunyavirus transmitted by biting midges, is the causative agent of Oropouche fever, which has caused multiple outbreaks in South and Central America. During the most recent epidemic in 2023-2025, >25,000 laboratory-confirmed cases were reported in Brazil, and no licensed antivirals have been reported to be effective date. In this study, we generated a recombinant OROV-expressing enhanced green fluorescent protein (rOROV/GFP) to facilitate rapid and sensitive antiviral evaluation. Growth kinetics demonstrated that rOROV/GFP replicated less efficiently than wild-type rOROV and that the historical prototype strain (BeAn19991) exhibited higher replication efficiency than the recent epidemic isolate (PE-IAM4637) in both Vero E6 and Huh7 cells. Using this system, we evaluated the antiviral activity of ribavirin, favipiravir (T-705), and remdesivir against OROV. All three compounds inhibited OROV replication in a dose-dependent manner, with remdesivir showing the greatest potency (IC₅₀ values of 0.31 µM). Taken together, our findings highlight remdesivir as a promising candidate for the treatment of Oropouche fever caused by OROV. Furthermore, we established rOROV/GFP as a powerful tool for antiviral drug screening.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Emerging Infectious Diseases, Institute of Tropical Medicine (NEKKEN), Nagasaki University, Nagasaki, Japan; Department of Emerging Infectious Diseases, National Research Center for the Control and Prevent…
- Department of Emerging Infectious Diseases, National Research Center for the Control and Prevention of Infectious Diseases (CCPID), Nagasaki University, Nagasaki, Japan; School of Tropical Medicine and Global Health, Na…
- Department of Emerging Infectious Diseases, National Research Center for the Control and Prevention of Infectious Diseases (CCPID), Nagasaki University, Nagasaki, Japan.
Förderung
- Japan Society for the Promotion of Science
- Japan Agency for Medical Research and Development
- Japan Science and Technology Agency
Zitieren
APA
Yoshikawa, R., Ishii, Y., Sano, N., & Yasuda, J. (2026). Remdesivir as a potent antiviral against prototype and current epidemic Oropouche virus strains (BeAn19991 and PE-IAM4637). Virus Research, 363, 199680. https://doi.org/10.1016/j.virusres.2025.199680
Vancouver
Yoshikawa R, Ishii Y, Sano N, Yasuda J. Remdesivir as a potent antiviral against prototype and current epidemic Oropouche virus strains (BeAn19991 and PE-IAM4637). Virus Research. 2026;363:199680. doi:10.1016/j.virusres.2025.199680
BibTeX
@article{Yoshikawa2026,
author = {Yoshikawa, Rokusuke and Ishii, Yoshiyasu and Sano, Naomi and Yasuda, Jiro},
title = {Remdesivir as a potent antiviral against prototype and current epidemic Oropouche virus strains (BeAn19991 and PE-IAM4637)},
journal = {Virus Research},
year = {2026},
volume = {363},
pages = {199680},
doi = {10.1016/j.virusres.2025.199680}
}
EUVIMED